US 8,133,872 B2 · Use of nicotinic acid adenine dinucleotide phosphate or derivative thereof as agent for treating type-2 diabetes

Abstract

The administration of nicotinic acid adenine dinucleotide phosphate (NAADP) or a pharmaceutically acceptable salt thereof to a host in need thereof for the treatment of type-2 diabetes has been disclosed.

Claims2

Dependent claims

A method of treating type-2 diabetes, which comprises administering an effective amount of nicotinic acid adenine dinucleotide phosphate or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment.

Dependencies are inferred from the claim text.

Facts

Application

12/468,600Filed 19 May 2009

Priority

KR 10-2008-004633519 May 2008

Published

US 2009/0306006 A110 Dec 2009

Granted

13 Mar 2012

Term ends

Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 31/7064
Containing six-membered rings with nitrogen as a ring hetero atom: containing condensed or non-condensed pyrimidines
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
A61P 5/50
Of the pancreatic hormones: for increasing or potentiating the activity of insulin
A61P 31/10
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antimycotics

Use of nicotinic acid adenine dinucleotide phosphate or derivative thereof as agent for treating type-2 diabetes

Life of this patent

Abstract

Claims2

Use of nicotinic acid adenine dinucleotide phosphate or derivative thereof as agent for treating type-2 diabetes

Life of this patent

Abstract

Claims2